Belotecan Hydrochloride/Cisplatin

盐酸贝洛替康/顺铂

Report date: 2022/03/23 14:30:59

Base Information

Drug NameBelotecan Hydrochloride/Cisplatin
Drug Alias Name盐酸贝洛替康+顺铂Belotecan Hydrochloride+CisplatinCisplatin/Belotecan Hydrochloride顺铂+贝洛替康CKD-602 + cisplatin, Chong Kun Dang +[15] 
ClassificationSmall molecules
Mechanisms of ActionDNA topoisomerase I inhibitorsAlkylating agentsDNA cross linking agents +[5] 
TargetsDNA topoisomerase IDNA
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes CisplatinBelotecan Hydrochloride
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChong Kun Dang Pharmaceutical Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChong Kun Dang Pharmaceutical Corp
Active IndicationsN/A
Inactive IndicationsSmall Cell Lung Carcinoma

Other Information

ATC CodeN/A
Related LinksN/A